Page 173 - 2020_08-Haematologica-web

NPM-ALK quantification by RQ-PCR and dPCR in ALCL
ual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. Blood. 2014;123(3): 334-337.
15. Hebart H, Lang P, Woessmann W. Nivolumab for refractory anaplastic large cell lymphoma: a case report. Ann Intern Med. 2016;165(8):607-608.
16. Gambacorti-Passerini C, Mussolin L, Brugieres L. Abrupt relapse of ALK-positive lymphoma after discontinuation of crizo- tinib. N Engl J Med. 2016;374(1):95-96.
17. Mosse YP, Voss SD, Lim MS, et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children's Oncology Group study. J Clin Oncol. 2017;35(28):3215-3221.
18. Branford S, Cross NC, Hochhaus A, et al. Rationale for the recommendations for har- monizing current methodology for detecting BCR-ABL transcripts in patients with chron- ic myeloid leukaemia. Leukemia. 2006;20 (11):1925-1930.
19. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmoniz- ing current methodology for detecting BCR- ABL transcripts and kinase domain muta- tions and for expressing results. Blood. 2006;108(1):28-37.
20. Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci U S A. 1999;96(16):9236-9241.
21. Dube S, Qin J, Ramakrishnan R. Mathematical analysis of copy number vari- ation in a DNA sample using digital PCR on a nanofluidic device. PloS One. 2008;3
(8):e2876.
22. Brugieres L, Pacquement H, Le Deley MC, et
al. Single-drug vinblastine as salvage treat- ment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol. 2009;27(30):5056-5061.
23. Mosse YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14(6):472-480.
24. Rigaud C, Abbou S, Minard-Colin V, et al. Efficacy of nivolumab in a patient with sys- temic refractory ALK+ anaplastic large cell lymphoma. Pediatr Blood Cancer. 2018;65 (4):e26902.
25. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-2196.
26. Gambacorti Passerini C, Farina F, Stasia A, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lym- phoma patients. J Natl Cancer Inst. 2014;106 (2):djt378.
27. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lym- phoma. N Engl J Med. 2011;364(8):775-776.
28. Locatelli F, Mauz-Koerholz C, Neville K, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multi- centre, open-label, phase 1/2 study. Lancet Haematol. 2018;5(10):e450-e461.
29. Woessmann W, Peters C, Lenhard M, et al. Allogeneic haematopoietic stem cell trans- plantation in relapsed or refractory anaplas- tic large cell lymphoma of children and ado- lescents--a Berlin-Frankfurt-Munster group report. Br J Haematol. 2006;133(2):176-182.
30. Gross TG, Hale GA, He W, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lym- phoma in children and adolescents. Biol Blood Marrow Transplant. 2010;16(2):223- 230.
31. Fukano R, Mori T, Kobayashi R, et al. Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adoles- cents in Japan. Br J Haematol. 2015;168(4): 557-563.
32. Strullu M, Thomas C, Le Deley MC, et al. Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lym- phoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC. Bone Marrow Transplant. 2015;50(6):795-801.
33. Mussolin L, Bonvini P, it-Tahar K, et al. Kinetics of humoral response to ALK and its relationship with minimal residual disease in pediatric ALCL. Leukemia. 2009;23(2): 400-402.
34. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349(15):1423-1432.
35. Cross NC, White HE, Muller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26(10):2172- 2175.
36. Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpre- tation of individual patient response and comparison of response rates between clini- cal trials. Blood. 2008;112(8):3330-3338.
37. White H, Deprez L, Corbisier P, et al. A cer-
tified plasmid reference material for the standardisation of BCR-ABL1 mRNA quan- tification by real-time quantitative PCR. Leukemia. 2015;29(2):369-376.
38. Pfeifer H, Cazzaniga G, van der Velden VHJ, et al. Standardisation and consensus guide- lines for minimal residual disease assess- ment in Philadelphia-positive acute lym- phoblastic leukemia (Ph+ ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukemia. 2019;33(8): 1910-1922.
39. Whale AS, Cowen S, Foy CA, Huggett JF. Methods for applying accurate digital PCR analysis on low copy DNA samples. PloS One. 2013;8(3):e58177.
40. Sanders R, Mason DJ, Foy CA, Huggett JF. Evaluation of digital PCR for absolute RNA quantification. PloS one. 2013;8(9):e75296.
41. Cavalli M, De Novi LA, Della Starza I, et al. Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lym- phoma. Br J Haematol. 2017;177(4):588-596.
42. Della Starza I, Nunes V, Cavalli M, et al. Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T- cell receptor gene rearrangements to moni- tor minimal residual disease in acute lym- phoblastic leukaemia. Br J Haematol. 2016;174(4):541-549.
43. Bonvini P, Zin A, Alaggio R, Pawel B, Bisogno G, Rosolen A. High ALK mRNA expression has a negative prognostic signifi- cance in rhabdomyosarcoma. Br J Cancer. 2013;109(12):3084-3091.
44. Jennings LJ, George D, Czech J, Yu M, Joseph L. Detection and quantification of BCR-ABL1 fusion transcripts by droplet dig- ital PCR. J Mol Diagn. 2014;16(2):174-179.
45. Iacobucci I, Lonetti A, Venturi C, et al. Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 tran- script in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response. Leuk Res. 2014;38(5):581-585.
46. Wang WJ, Zheng CF, Liu Z, et al. Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression. Eur J Haematol. 2018; 101(3):291-296.
47. Huggett JF, Foy CA, Benes V, et al. The digital MIQE guidelines: minimum information for publication of quantitative digital PCR exper- iments. Clin Chem. 2013;59(6):892-902.
48. Huggett JF, Cowen S, Foy CA. Considerations for digital PCR as an accu- rate molecular diagnostic tool. Clin Chem. 2015;61(1):79-88.
haematologica | 2020; 105(8)
2149